Experimental combo targets tough leukemia in early trial
NCT ID NCT06768476
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This early-phase study tests whether combining CART123 cells (a type of immune cell therapy) with the drug ruxolitinib is safe and feasible for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Twelve participants will receive a single infusion of CART123 cells after chemotherapy and ruxolitinib. The main goal is to check for side effects and see if the treatment plan can be completed as designed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY AML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.